Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study-Reference-Cited by-同舟云学术

Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study

Published:2021-08 Issue: Volume:174 Page:106653
ISSN:0920-1211
Container-title:Epilepsy Research
language:en
Short-container-title:Epilepsy Research

Author:

Sales Francisco,Delanty Norman,Mecarelli Oriano,Holtkamp Martin,McMurray Rob,Loureiro Rui^ORCID,Fernandes Hélder^ORCID,Villanueva Vicente

Funder

Eisai

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference21 articles.

1. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: a subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures;Abou-Khalil;Epilepsy Res.,2018

2. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects;Almeida;Acta Neurol. Scand.,2010

3. Aptiom® (eslicarbazepine acetate) Prescribing Information, 2019. Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA.

4. The evolution of antiepileptic drug development and regulation;Arzimanoglou;Epileptic Disord.,2010

5. Data from regulatory studies: what do they tell? What don’t they tell?;Ben-Menachem;Acta Neurol. Scand., Suppl.,2005

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PERPRISE: A prospective non‐interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic‐clonic seizures: First interim analysis;Epilepsia Open;2023-11-28

2. Real-world analysis of retention on cenobamate in patients with epilepsy in the United States;Epilepsy Research;2023-11